TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 892 participants.
Also called NCT01090037
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 892 participants
- Sponsor
- Registry
-
NCT01090037
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China, Hong Kong SAR China, Japan, Malaysia, South Korea, Taiwan, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT01090037. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2014-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)
- Condition
- Chronic Renal Failure
- Condition
- Glomerular Disease
- Condition
- Nephrosclerosis
- Intervention (Drug)
- TRK-100STP high dose
- Intervention (Drug)
- TRK-100STP low dose
- Intervention (Drug)
- Placebo
- Lead sponsor
- Toray Industries, Inc
- Collaborator
- Astellas Pharma Inc
Record details
- Record id
cardio:ct-nct01090037- Content hash
60fd20a817b94b3a8f2ba808bb2a22d6999548372ccdd9378e17fd3e4130acd1